Larson Financial Group LLC Acquires 2,135 Shares of STAAR Surgical (NASDAQ:STAA)

Larson Financial Group LLC grew its holdings in shares of STAAR Surgical (NASDAQ:STAA) by 78.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,863 shares of the medical instruments supplier’s stock after purchasing an additional 2,135 shares during the quarter. Larson Financial Group LLC’s holdings in STAAR Surgical were worth $181,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Intech Investment Management LLC bought a new position in shares of STAAR Surgical during the 3rd quarter valued at $463,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in STAAR Surgical by 323.4% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 30,014 shares of the medical instruments supplier’s stock worth $1,115,000 after acquiring an additional 22,925 shares during the period. LMR Partners LLP raised its holdings in STAAR Surgical by 2.2% in the 3rd quarter. LMR Partners LLP now owns 34,712 shares of the medical instruments supplier’s stock worth $1,290,000 after acquiring an additional 743 shares during the period. Quest Partners LLC bought a new position in STAAR Surgical in the 3rd quarter worth $128,000. Finally, Geneva Capital Management LLC raised its holdings in STAAR Surgical by 0.3% in the 3rd quarter. Geneva Capital Management LLC now owns 695,415 shares of the medical instruments supplier’s stock worth $25,835,000 after acquiring an additional 2,241 shares during the period. Institutional investors own 96.70% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. Stifel Nicolaus dropped their target price on shares of STAAR Surgical from $50.00 to $44.00 and set a “buy” rating on the stock in a report on Monday, August 26th. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a report on Thursday, October 31st. Finally, Canaccord Genuity Group dropped their target price on shares of STAAR Surgical from $41.00 to $31.00 and set a “hold” rating on the stock in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $43.33.

STAAR Surgical Price Performance

NASDAQ STAA opened at $28.18 on Thursday. The firm has a market capitalization of $1.39 billion, a price-to-earnings ratio of 64.05 and a beta of 0.61. The company’s fifty day moving average is $30.74 and its two-hundred day moving average is $36.37. STAAR Surgical has a 52-week low of $25.88 and a 52-week high of $52.68.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.